Skip to main content

Table 3 Predictive factors of AA treatment duration

From: Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

  Univariate analysis   Multivariate analysis  
  OR p OR p
Age <60 vs 1 0.107   
> = 60 0.57 95% CI [0.29-1.13]
Gleason score 4-6 1    
7 1.24 95% CI [0.45-3.39] 0.68
8-10 1.16 95% CI [0.44-3.05] 0.76
Duration of CT before AA treatment <=4 months 1    
]4-6] 0.99 95% [0.42-2.31] 0.98
[6-9] 2.00 95% [0.81-4.98] 0.13
>9 1.17 95% [0.53-2.59] 0.70
PSA baseline before CT Continuous variable 0.99 95% [0.99-1.00] 0.10   
PSA baseline before AA Continuous variable 1.00 95% [0.99-1.00] 0.67   
Sites of metastasis Bone or visceral alone vs Multiple 1 0.17 1  
0.65 95% CI [0.36-1.19]   0.71 95% [0.35-1.44] 0.34
Number of CT lines 1 1    
2 1.02 95% [0.53-1.99] 0.94
3 1.23 95% [0.33-4.56] 0.75
4-5 0.26 95% [0.02-4.34] 0.35
PSA variation at 3 months Decrease 1 <0.0001 1  
Increase 0.06 95% [0.02-0.19]   0.13 95% [0.06-0.31] <0.0001